股票 
板块 
用户 
资讯 Shanghai, August 5, 2026 — Shanghai Haoyuan Chemexpress Co., Ltd. ("ChemExpress") and Anhui Orivie Technology Co., Ltd. ("Orivie Technology") officially signed a strategic partnership agreement.
Guided by the principles of complementary strengths, resource sharing, collaborative innovation, and mutual benefit, ChemExpress will work closely with Orivie Technology to leverage both companies' industry resources, technology platforms, and service capabilities across multiple areas. Together, we aim to build a highly integrated service ecosystem and drive innovation and sustainable growth across the biopharmaceutical industry.
Dr. Baofu Zheng, Founder and CEO of ChemExpress (right), and Mr. Yang Liu, Chairman of Orivie Technology and Founder and Chairman of SAIFU Lab (left), sign the strategic partnership agreement.
As pharmaceutical innovation continues to evolve globally, the rapid advancement of small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs is accelerating the need for integrated CRO & CDMO partners capable of delivering seamless support across the entire drug development lifecycle.
At ChemExpress, we have established an integrated service platform spanning drug discovery, process development, and the development and manufacturing of starting materials, novel building blocks, intermediates, APIs, biologics, and drug products. We have built deep technical expertise and extensive project experience across small molecules, biologics, and new modalities.
Orivie Technology focuses on innovative therapeutics, medical devices, and CXO services, and has established a full-lifecycle drug development service platform spanning nonclinical research and clinical development. Its acquisition of United-Power Pharma, a leading CRO in bioanalysis, is expected to strengthen its bioanalytical capabilities across new modalities such as cell and gene therapies, ADCs, peptides, and oligonucleotides. It is also advancing plans for a non-human primate breeding facility in Chizhou, Anhui Province, to strengthen its preclinical service network. The company is committed to building an innovative drug development ecosystem that creates synergies between capital and industry.
Through this strategic partnership, We will further align our industry resources and specialized capabilities, explore collaboration opportunities across innovative drug development and commercialization, and strengthen the integration of technology platforms, project resources, and service capabilities. The partnership will provide industry partners with more integrated and efficient support from drug R&D through commercialization. By combining our capital markets expertise and industry capabilities, we will create deeper synergies between capital and industry.
Mr. Yang Liu
Chairman of Orivie Technology
& Founder and Chairman of SAIFU Lab
"Orivie Technology is advancing the development of its capital–industry 'Empower Ecosystem Platform' through a series of strategic mergers and acquisitions—with the acquisition of United-Power Pharma, a leading CRO in innovative-drug bioanalysis, as a key step, " said Mr. Yang Liu, Chairman of Orivie Technology and Founder and Chairman of SAIFU Lab.
"We are also advancing plans for a non-human primate breeding facility in Chizhou, Anhui Province, to strengthen our nonclinical research value chain. ChemExpress' integrated capabilities spanning drug discovery, CMC development, and commercial manufacturing are highly aligned with Orivie Technology's vision of building a full-lifecycle ecosystem for innovative drug development. Through this strategic partnership, our two companies will establish a long-term strategic relationship and combine our capital resources and industry expertise. Together, we aim to further develop the biopharmaceutical investment fund ecosystem and provide promising innovative drug programs with end-to-end support from R&D through commercialization."
Dr. Baofu Zheng
Founder and CEO of ChemExpress
"At ChemExpress, our 'Client-Focused, Innovation-Driven' philosophy is at the heart of everything we do," said Dr. Baofu Zheng, Founder and CEO of ChemExpress. "We are committed to empowering global innovators with integrated, end-to-end CRO & CDMO solutions that span drug discovery, CMC development, and commercial manufacturing. By streamlining the development journey, we aim to improve efficiency, accelerate time to market, and ultimately help bring innovative therapies to patients faster."
"Orivie Technology's strong expertise in nonclinical research and clinical bioanalytical testing complements our integrated platform exceptionally well. More importantly, we share a common vision of building a collaborative ecosystem that supports the entire drug development lifecycle. Through this strategic partnership, we will combine our complementary strengths and further integrate our technology platforms, scientific expertise, and service capabilities. Together, we are well positioned to provide seamless support from early discovery through clinical development and commercialization, enabling our global partners to advance innovative medicines with greater speed, quality, and confidence."
About Orivie Technology
Headquartered in Hefei, Anhui Province, Orivie Technology is a listed company with biomedicine as its primary growth engine, anchored in the innovative drugs, medical devices, and CXO sectors as it transforms.
Leveraging the industrial resources and capital-operation expertise of its actual controller in the biomedicine field, the company is accelerating its industrial footprint through a series of strategic mergers and acquisitions — including the acquisition of United-Power Pharma, a leading CRO in innovative-drug bioanalysis.
A non-human primate breeding facility is also in the planning and preparation stage in Chizhou, Anhui Province, to strengthen the company's nonclinical research capabilities. Together, these initiatives support the development of Orivie Technology's capital–industry "Empower Ecosystem Platform" and the continued expansion of its biopharmaceutical operations.
Committed to long-term value creation, Orivie Technology aims to become a world-class integrated technology platform spanning life sciences and the green economy.
About ChemExpress
Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and new modalities such as ADCs/XDCs, peptides and PROTACs. Our comprehensive platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs, biologics and drug products. We support our clients' projects from early drug discovery, process development to commercialization. Over the past 20 years, we have established a state-of-the-art QC/QA system aligning with ICH guidelines for pharmaceutical manufacturing. We provide our clients with high-quality products and CMC services across the entire lifecycle of drug development. For more information, please visit: www.chemexpress.com.
精选推送
相关阅读
对话国际 聚力致远｜UNGC驻华代表刘萌到访皓元医药，共谋医药可持续发展新局
皓元医药重庆基地投产一周年，交出“硬核答卷”
聚焦“十五五”规划 | 皓元医药董事长郑保富作为上海民营企业代表赴京参会
聚焦源头创新 皓元医药参设百济沃杰基金 深化研发全周期服务布局
皓力同心，元聚山海 | 皓元医药二十周年庆典暨2026年迎新春盛典圆满举行
关于皓元医药
ABOUT US
上海皓元医药股份有限公司（股票代码：688131）成立于2006年，专注于为全球制药和生物医药行业提供小分子、大分子及新分子类型药物发现领域的生命科学试剂的研发，原料药、中间体、起始物料及制剂的药物研发，工艺优化及商业化生产。公司始终将创新作为核心驱动力，以“产品+服务”模式，聚焦差异化发展，致力于打造覆盖药物研发及生产“起始物料 - 中间体 - 原料药 - 制剂”的一体化服务平台，加速赋能全球合作伙伴实现从临床前到商业化生产的全过程，让药物研发更高效，更快上市，更早惠及人类健康。
在生命科学试剂业务领域，公司已成为全球领先的科研化学品和生物试剂供应商，在中间体、特色原料药和制剂业务领域，公司致力于打造客户信赖的全球CRO&CDMO合作伙伴，在ADC早期发现到CDMO比较细分专业领域中，公司处于第一梯队。目前，公司已与多个地区的知名医药企业、科研院所、CRO公司建立了深度合作关系，被评为国家级专精特新“小巨人”企业、国家知识产权优势企业、上海市创新型企业总部、上海市企业技术中心等，荣登“上海硬核科技企业TOP100榜单”，荣获“科创板硬科技领军企业”、“中国医药CDMO企业20强”、中国科促会“科技创新奖一等奖”、“CPHI China医药国际化领军企业奖”、2025硬科硬客“出海先锋奖”等多项荣誉称号。
未来，公司将持续围绕“产业化、全球化、品牌化”发展战略，坚持“一切为了客户，一切源于创新”的服务宗旨，深耕小分子类型药物研发服务与产业化应用市场，积极向大分子、新分子类型深度拓展，打造具有国际竞争力的、世界一流的医药研发和生产服务企业，推动研发创新以改善全球病患的生存状态和生活质量。
本文仅作推广用途，不构成任何投资建议，相关信息披露内容请以公司公告为准。敬请投资者注意投资风险，理性决策，审慎投资。
版权说明：本文由皓元医药原创发布，未经授权谢绝转载改编，欢迎个人分享至朋友圈。转载授权请直接在「皓元医药」微信公众号留言联系，并注明“贵方公众号名称+拟转载文章标题”，我们将进行内部评估。感谢您对我们推送内容的认同。
为皓元点赞、“在看”
评论 (0)